rdf:type |
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0018133,
umls-concept:C0039194,
umls-concept:C0085358,
umls-concept:C0439851,
umls-concept:C0574032,
umls-concept:C0591833,
umls-concept:C1280500,
umls-concept:C1332714,
umls-concept:C1332717,
umls-concept:C1366561,
umls-concept:C1413243,
umls-concept:C1413244,
umls-concept:C1552596,
umls-concept:C1706438,
umls-concept:C1947931,
umls-concept:C2698600
|
pubmed:issue |
8
|
pubmed:dateCreated |
1996-12-17
|
pubmed:abstractText |
Efficient T cell proliferation requires costimulation via CD28/B7 or other pathways. Graft-vs-host disease (GVHD) is caused by activated donor T cells. We have found that the infusion of anti-B7.1 (CD80) + anti-B7.2 (CD86) mAb is effective in eliminating GVHD lethality induced by either CD8+ or CD4+ T cells. Donor CD4+ and CD8+ T cell expansion was inhibited by almost 100-fold as measured by enumerating thoracic duct lymphocytes (TDL) obtained early post-transplant. TDL retained anti-host responsiveness indicating that not all T cells were anergic. Although anti-CD80 or anti-CD86 mAb individually were ineffective in preventing CD8+ T cell GVHD lethality, each mAb was partially effective in CD4+ T cell-mediated GVHD. Because CD80 expression was found to be up-regulated on donor CD4+ TDL post-transplant, the GVHD capacity of donor CD4+ T cells deficient in CD80 was tested and found to be reduced similarly to that seen with anti-CD80 mAb. These studies demonstrate that anti-CD80 + anti-CD86 mAb infusion is effective in preventing GVHD lethality by inhibiting donor CD4+ or CD8+ T cell expansion and provide the first evidence that CD80 expression on donor T cells is critical for optimal GVHD lethality.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD80,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD86,
http://linkedlifedata.com/resource/pubmed/chemical/Cd86 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class II,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0022-1767
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
157
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3250-9
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8871619-Animals,
pubmed-meshheading:8871619-Antibodies, Monoclonal,
pubmed-meshheading:8871619-Antigens, CD,
pubmed-meshheading:8871619-Antigens, CD80,
pubmed-meshheading:8871619-Antigens, CD86,
pubmed-meshheading:8871619-Bone Marrow Transplantation,
pubmed-meshheading:8871619-CD4-Positive T-Lymphocytes,
pubmed-meshheading:8871619-CD8-Positive T-Lymphocytes,
pubmed-meshheading:8871619-Graft vs Host Disease,
pubmed-meshheading:8871619-Histocompatibility Antigens Class II,
pubmed-meshheading:8871619-Infusions, Intravenous,
pubmed-meshheading:8871619-Membrane Glycoproteins,
pubmed-meshheading:8871619-Mice,
pubmed-meshheading:8871619-Mice, Inbred C57BL,
pubmed-meshheading:8871619-Mice, Mutant Strains,
pubmed-meshheading:8871619-Mice, SCID
|
pubmed:year |
1996
|
pubmed:articleTitle |
Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
|
pubmed:affiliation |
Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|